lundi 24 octobre 2016

Onco Actu du 24 octobre 2016

3.1 Tabac

Anti-smoking experts to sue Times for claims of tobacco payouts [The Guardian]

3.3 Prévention - Vaccins

GSK exits U.S. market with its HPV vaccine Cervarix [FiercePharma]

3.6 Prévention - Activité physique

Pokemon Go Increased U.S. Activity Levels by 144 Billion Steps in Just 30 Days [MIT Technology Review]

4.12 Biopsies liquides

The perfect match: making breast cancer treatment more personal [Cancer Research UK]

5. Traitements

The Drug Development Paradigm in Oncology: A Workshop [National Academies]

5.12 Immunothérapies

Is immunotherapy the wrong choice for some lung cancer patients? [Grace]

Hot on the heels of its Bristol-Myers slapdown, Merck scores PhIII bladder cancer success with Keytruda [EndPoints]

Merck's Keytruda succeeds in key bladder cancer trial [Reuters]

Merck’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early [Merck]

5.2 Pharma

Roche adjusts Avastin franchise defense plans as PhII successor fails a key study [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients With Advanced Form of Bladder Cancer [BMS]

5.3.4 Traitements - AMM (FDA, EMA)

FDA Approves Supplemental New Drug Application for XTANDI in Advanced Prostate Cancer [Astellas]

5.4 Traitements - Economie

Understanding today’s drug pricing environment [European Pharmaceutical Review]

6. Lutte contre les cancers

Too much needless NHS treatment says Royal College, as it draws up list of those with little or no benefit [The Telegraph]

6.10 Politiques

NHS access to innovative drugs could be cut by four years, says review [The Guardian]

6.10.1 Politiques (USA)

Sanders urges Californians to approve drug price ballot measure [Reuters]

6.11 Patients

The Books My Dad Won’t Read? Mine [NY Times]

6.6 Publications

Cancer researcher retracts 19 studies at once [Retraction Watch]

6.7 DMP, Big Data & applis

NCI picks Amazon, Microsoft for cloud data project [FierceBiotech]

The Limits of Big Data [In the Pipeline]